Pan‐cancer population pharmacokinetics and exposure‐safety and ‐efficacy analyses of atezolizumab in patients with high tumor mutational burden

Abstract We retrospectively investigated the pharmacokinetics and exposure‐efficacy/safety relationships of single‐agent atezolizumab based on tissue tumor mutational burden (tTMB) status (high vs low [≥16 vs <16 mutations/megabase]) in a pan‐tumor population from seven clinical trials. Data sources...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Colby S. Shemesh, Phyllis Chan, Fatema A. Legrand, David S. Shames, Meghna Das Thakur, Jane Shi, Lorna Bailey, Shweta Vadhavkar, Xian He, Wei Zhang, René Bruno
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Wiley 2020-12-01
Ráidu:	Pharmacology Research & Perspectives
Fáttát:	atezolizumab biomarkers clinical pharmacology mutation pharmacokinetics tumor
Liŋkkat:	https://doi.org/10.1002/prp2.685
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!